CorriXR Therapeutics Promotes Eric Kmiec to CEO Position
CorriXR Therapeutics, Inc., a prominent biotherapeutics company specializing in oncology, has exciting news: Dr. Eric B. Kmiec, the founder and chief scientific officer of the company, has taken on the role of chief executive officer. His transition into this pivotal role is expected to enhance CorriXR's mission to develop cutting-edge treatments in the fight against cancer.
A Vision for Transformative Healthcare
Dr. Kmiec's appointment has garnered positive support from the Board of Directors, particularly from Dr. Janice Nevin, who emphasizes the confidence in Eric's leadership capabilities to navigate CorriXR into a promising future. Under his guidance, the company aims to leverage its groundbreaking gene editing technology, known for its potential to significantly elevate patient care and health outcomes.
Innovative Research Background
In addition to his responsibilities at CorriXR, Dr. Kmiec also serves as the executive director and chief scientific officer of ChristianaCare's Gene Editing Institute. His extensive research work has focused on CRISPR-directed genome engineering and gene repair. With more than three decades of NIH-funded research under his belt, and an impressive list of 175 peer-reviewed publications and 15 patents, Dr. Kmiec is widely recognized for his innovative contributions to molecular medicine, particularly in the area of oncology.
Seamless Transition in Leadership
As the company transitions into this new phase, it is noteworthy that former CEO Deborah Moorad decided to step down from her role. Her decision allows her to continue contributing to the life sciences arena while passing the reins to Eric. The Board expressed deep gratitude for Deborah's leadership, recognizing her vital contributions that have shaped CorriXR into the dynamic company it is today.
Strategic Development Ahead
CorriXR is poised for significant developments as it prepares for its Series A financing round and its inaugural clinical trial. The company is uniquely positioned at this critical juncture, with a focus on utilizing its proprietary gene editing technology to combat drug resistance in solid tumors. The primary area of focus is currently on squamous cell carcinoma of the head and neck, which stands to benefit immensely from these advancements.
About CorriXR Therapeutics
CorriXR Therapeutics, Inc. is at the forefront of biotherapeutic innovation in oncology, employing a proprietary, IP-protected in vivo gene editing platform. As the first biotech spin-out from ChristianaCare and its Gene Editing Institute, which has been influential in cancer research since 2015, CorriXR aims to reshape cancer treatment by directly addressing the challenges of drug resistance in solid tumors.
Frequently Asked Questions
Who is the new CEO of CorriXR Therapeutics?
Eric B. Kmiec, Ph.D. has been appointed as the new CEO of CorriXR Therapeutics.
What is the focus of CorriXR Therapeutics?
CorriXR focuses on developing innovative biotherapeutics in oncology, particularly addressing drug resistance in solid tumors.
What experience does Eric Kmiec bring to his new role?
Eric Kmiec has over 35 years of NIH-funded research experience and is recognized for his pioneering work in gene editing, particularly CRISPR technologies.
What are CorriXR's upcoming plans?
CorriXR is preparing for a Series A financing round and its first clinical trial aimed at targeting squamous cell carcinoma.
How has the leadership changed at CorriXR?
Former CEO Deborah Moorad stepped down, allowing Eric Kmiec to take over the leadership role to advance the company's objectives.
